Abstract
BACKGROUND Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressively debilitating disease caused by transthyretin (TTR) gene mutations. The V122I variant, a common pathogenic TTR mutation found primarily in individuals of West African descent, is frequently associated with cardiomyopathy.
METHODS The association between the V122I variant and ICD10 diagnosis codes was assessed in the UK Biobank black subpopulation (N=6062); whether significant associations could be replicated in the Penn Medicine Biobank (N=5737) and Million Veteran Program (N=82,382) was then investigated. Cumulative incidence of common hATTR amyloidosis manifestations (polyneuropathy, carpal tunnel syndrome, cardiomyopathy, and heart failure) was estimated by V122I genotype in the UK Biobank using Cox regression controlling for age, sex, and genetic ancestry.
RESULTS Phenome-wide analysis identified a significant association between V122I genotype and polyneuropathy diagnosis (odds ratio [OR]=6.4, 95% confidence interval [CI]=2.6–15.6, P=4.2×10−5) in the UK Biobank. A significant association was also observed in the Penn Medicine Biobank (OR=1.6, 95% CI=1.2–2.4, P=6.0×10−3) and the Million Veteran Program (OR=1.5, 95% CI=1.2–1.8, P=1.8×10−4). Prevalence of a polyneuropathy diagnosis among V122I carriers was 2.1%, 9.0%, and 4.8% in the UK Biobank, Penn Medicine Biobank, and Million Veteran Program, respectively. In the UK Biobank, common hATTR amyloidosis manifestations were significantly enriched in V122I carriers compared with non-carriers (HR=2.8; 95% CI=1.7–4.5; P=2.6×10−5). By age 75, 37.4% of V122I carriers had a diagnosis of any one of the common manifestations, including polyneuropathy (7.9%).
CONCLUSIONS V122I carriers, historically associated with a predominantly cardiac phenotype of hATTR amyloidosis, have a significantly increased risk of polyneuropathy.
Competing Interest Statement
Conflict of Interest Disclosures: Drs Parker, Erbe, Aldinc, Ticau, Fitzgerald, Vaishnaw, and A.O. Flynn-Carroll are employees and stockholders of Alnylam Pharmaceuticals. Drs Deaton, Ward, and Nioi are employees and stockholders of Alnylam Pharmaceuticals and former employees of Amgen Inc. Dr Hinkle is an employee and stockholder of Alnylam Pharmaceuticals, reports personal fees from 54gene and has a patent US8168775B2 issued. Dr Damrauer reports grants from U.S. Department of Veterans Affairs and RenalytixAI, and personal fees from Calico Labs. Dr Hawkins reports personal fees from Alnylam Pharmaceuticals. Dr Gillmore reports grants and personal fees from Alnylam Pharmaceuticals, and personal fees from Akcea and Eidos Therapeutics. Dr Lynch is an employee with the federal government, Department of Veterans Affairs, and has received grants from the Department of Veteran Affairs. Dr Joseph has received research grants from U.S. Department of Veteran Affairs Office of Research and Development, Novartis, Kowa, Otsuka, and Amgen. Dr Tsao reports grants from U.S. Department of Veteran Affairs Office of Research and Development. Dr Chang is an employee with the federal government, Department of Veterans Affairs, has research funding from the Department of Veteran Affairs, and serves on the scientific advisory board for Arbutus, Inc. Dr Rader reports personal fees from Alnylam Pharmaceuticals, Novartis, and Pfizer. Drs Tcheandjieu, Hull, and Assimes have nothing to disclose.
Funding Statement
Analysis of the UK Biobank data is funded by Alnylam Pharmaceuticals Inc. Dr Damrauer is supported by the U.S. Department of Veterans Affairs (IK2-CX001780). Analysis of the VA Million Veteran Program data is supported by the U.S. Department of Veterans Affairs (I01-BX003362l and VA HSR RES 13-457). This publication does not represent the views of the U.S. Department of Veterans Affairs or the U. S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study was approved by the National Health Service National Research Ethics Service (ref. 11/NW/0382) and all participants provided written informed consent to participate in the UK Biobank study. Information about ethics oversight in the UK Biobank can be found at https://www.ukbiobank.ac.uk/ethics/. This research has been conducted using the UK Biobank resource, application no. 26041. The Penn Medicine Biobank research was approved by the Institutional Review Boards of the University of Pennsylvania (Protocol numbers: 808346(CGI), 813913 (PMBB), and 817977 (PMBB tissue). The Million Veterans Program research was approved by the Institutional Review Boards of the Veterans Affairs (Protocol number 19-06 - Genetics of Cardiometabolic Diseased in the VA Population II). Drs Parker, Damrauer, and Tcheandjieu had full access to the UK Biobank, Penn Medicine Biobank, and Million Veteran Program data analyzed in the study, respectively, and take responsibility for the integrity of the data and the accuracy of data analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data is available upon application to the UK Biobank.
